Literature DB >> 34390232

Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34390232      PMCID： PMC8411321          DOI： 10.1002/npr2.12193

Source DB:  PubMed          Journal:  Neuropsychopharmacol Rep        ISSN： 2574-173X


× No keyword cloud information.
  496 in total

1.  Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study.

Authors:  Georgios Petrides; Chitra Malur; Raphael J Braga; Samuel H Bailine; Nina R Schooler; Anil K Malhotra; John M Kane; Sohag Sanghani; Terry E Goldberg; Majnu John; Alan Mendelowitz
Journal:  Am J Psychiatry       Date:  2014-10-31       Impact factor: 18.112

2.  Antipsychotic medication and cognitive function in schizophrenia.

Authors:  Hiroaki Hori; Hiroko Noguchi; Ryota Hashimoto; Tetsuo Nakabayashi; Mayu Omori; Sho Takahashi; Ryotaro Tsukue; Kimitaka Anami; Naotsugu Hirabayashi; Seiichi Harada; Osamu Saitoh; Masao Iwase; Osami Kajimoto; Masatoshi Takeda; Shigeo Okabe; Hiroshi Kunugi
Journal:  Schizophr Res       Date:  2006-06-21       Impact factor: 4.939

3.  Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride.

Authors:  M Lambert; B G Schimmelmann; D Naber; F-X Eich; H Schulz; C G Huber; A Karow
Journal:  Pharmacopsychiatry       Date:  2009-11-18       Impact factor: 5.788

4.  Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders.

Authors:  P König; K Chwatal; L Havelec; F Riedl; H Schubert; H Schultes
Journal:  Neuropsychobiology       Date:  1996       Impact factor: 2.328

5.  A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism.

Authors:  J Schmider; H Standhart; M Deuschle; J Drancoli; I Heuser
Journal:  Biol Psychiatry       Date:  1999-08-01       Impact factor: 13.382

Review 6.  A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

Authors:  Neil D Woodward; Scot E Purdon; Herbert Y Meltzer; David H Zald
Journal:  Int J Neuropsychopharmacol       Date:  2005-03-23       Impact factor: 5.176

7.  Is propranolol effective in primary polydipsia?

Authors:  Y Kishi; H Kurosawa; S Endo
Journal:  Int J Psychiatry Med       Date:  1998       Impact factor: 1.210

Review 8.  Dose response and dose equivalence of antipsychotics.

Authors:  John M Davis; Nancy Chen
Journal:  J Clin Psychopharmacol       Date:  2004-04       Impact factor: 3.153

Review 9.  Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials.

Authors:  Markus Dold; Chunbo Li; Donna Gillies; Stefan Leucht
Journal:  Eur Neuropsychopharmacol       Date:  2013-04-17       Impact factor: 4.600

10.  Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.

Authors:  Linmarie Sikich; Jean A Frazier; Jon McClellan; Robert L Findling; Benedetto Vitiello; Louise Ritz; Denisse Ambler; Madeline Puglia; Ann E Maloney; Emily Michael; Sandra De Jong; Karen Slifka; Nancy Noyes; Stefanie Hlastala; Leslie Pierson; Nora K McNamara; Denise Delporto-Bedoya; Robert Anderson; Robert M Hamer; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2008-09-15       Impact factor: 18.112
View more
  5 in total

1.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

2.  Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study.

Authors:  Jun Ishigooka; Kazuyuki Nakagome; Tetsuro Ohmori; Nakao Iwata; Ken Inada; Jun-Ichi Iga; Taro Kishi; Kiyoshi Fujita; Yuka Kikuchi; Toshiaki Shichijo; Hideaki Tabuse; Shotatsu Koretsune; Hiroshi Terada; Haruko Terada; Toshifumi Kishimoto; Yuichiro Tsutsumi; Yoshiki Kanda; Kazutaka Ohi; Kanji Sekiyama
Journal:  Psychiatry Clin Neurosci       Date:  2021-11-17       Impact factor: 12.145

3.  Changes in psychotropic polypharmacy and high-potency prescription following policy change: Findings from a large scale Japanese claims database.

Authors:  Masahiro Takeshima; Minori Enomoto; Masaya Ogasawara; Mizuki Kudo; Yu Itoh; Kazuhisa Yoshizawa; Dai Fujiwara; Yoshikazu Takaesu; Kazuo Mishima
Journal:  Psychiatry Clin Neurosci       Date:  2022-07-02       Impact factor: 12.145

4.  Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry.

Authors:  Kazuyoshi Ogasawara; Shusuke Numata; Naomi Hasegawa; Masahito Nakataki; Manabu Makinodan; Kazutaka Ohi; Masahiro Takeshima; Takashi Tsuboi; Naoki Hashimoto; Toshiaki Onitsuka; Hiroyuki Muraoka; Hikaru Hori; Kayo Ichihashi; Takahiko Inagaki; Norio Yasui-Furukori; Akitoyo Hishimoto; Nobuhiro Sugiyama; Kentaro Fukumoto; Tatsuya Nagasawa; Junya Matsumoto; Yoshikazu Takaesu; Ryuji Furihata; Kiyotaka Nemoto; Toshinori Nakamura; Masahide Usami; Kenichiro Miura; Michiko Fujimoto; Hiromi Tagata; Hisashi Yamada; Hiroshi Komatsu; Shinichiro Ochi; Kiyokazu Atake; Eiichi Katsumoto; Mikio Kido; Taishiro Kishimoto; Taro Suwa; Satoshi Yamamura; Jun-Ichi Iga; Hitoshi Iida; Ken Inada; Koichiro Watanabe; Ryota Hashimoto
Journal:  Neuropsychopharmacol Rep       Date:  2022-03-10

5.  Effects of medical service fee revision on reducing irrational psychotropic polypharmacy in Japan: an interrupted time-series analysis.

Authors:  Yusuke Okada; Manabu Akazawa
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2021-07-31       Impact factor: 4.328
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.